Skip to Main Content

Paper Details

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Neuro Oncol
74
2022
CNS tumors, HGG, LGG, Larotrectinib, Patients, TRK, TRK fusion, cancer, high-grade glioma, larotrectinib, low-grade glioma, patients, primary, primary CNS tumors, primary central nervous system (CNS) tumors, primary central nervous system tumors, tropomyosin receptor kinase
Author NameAffiliation
Fran??ois DozSIREDO Oncology Center (Care, Institut Curie and Universite de Paris
Fran??ois DozSIREDO Oncology Center (Care, Institut Curie and Universite de Paris
Cornelis M van TilburgHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ)
Ingrid ÿraSkane University Hospital, Lund & Karolinska University Hospital
Steven G DuBois
Nicolas U GerberUniversity Children's Hospital
David S ZieglerKids Cancer Centre, Sydney Children's Hospital
David S ZieglerUniversity of New South Wales Sydney
Alexander DrilonMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
  • 1 - 9

Datasets

Release 1.2